Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone ( VRd ) as first‐line therapy in multiple myeloma-Reference-Cited by-同舟云学术

Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone ( VRd ) as first‐line therapy in multiple myeloma

Published:2021-01-13 Issue:3 Volume:96 Page:330-337
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Cook Joselle¹^ORCID,Johnson Isla²,Higgins Alexandra¹^ORCID,Sidana Surbhi¹³^ORCID,Warsame Rahma¹^ORCID,Gonsalves Wilson¹^ORCID,Gertz Morie A.¹^ORCID,Buadi Francis¹,Lacy Martha¹,Kapoor Prashant¹,Dispenzieri Angela¹^ORCID,Kourelis Taxiarchis¹^ORCID,Dingli David¹,Fonder Amie¹,Hayman Suzanne¹,Hobbs Miriam¹,Hwa Yi Lisa¹^ORCID,Kyle Robert¹,Leung Nelson¹^ORCID,Go Ronald¹,Rajkumar Vincent S.¹^ORCID,Kumar Shaji¹

Affiliation:

1. Division of Hematology Mayo Clinic Rochester Minnesota USA

2. Department of Internal Medicine Mayo Clinic Rochester Minnesota USA

3. Department of Medicine Stanford University Stanford California USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26074

Reference33 articles.

1. Multiple Myeloma: Diagnosis and Treatment